Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.
The acquisition of the site in Windlesham, Surrey is expected to be completed in November 2020, and reflects UCB’s commitment to retain the UK as one of its three global hubs for research and development alongside Belgium and the US.
“I am delighted to have signed an agreement to secure this new campus for our UK hub, from which our scientists will be able to continue to develop their extensive collaborations with some of the most innovative universities, biotechs and medical research charities, bringing even greater benefit for patients,” said Jean-Christophe Tellier, chief executive officer of UCB.
UCB has projected its investment in the UK – including the new site – to be more than £1bn over five years, with the transition to this new facility set to support over 650 high-value jobs in scientific research, translational medicine, clinical development, early manufacturing and commercial roles.
Following the completion of the acquisition, the campus will undergo refurbishment prior to UCB relocating from its current UK headquarters in Slough, Berkshire.
The refurbishment will also enable UCB to execute its research plan to develop innovative treatments for patients, including gene therapies and translational medicines, as well as development of its antibody discovery platforms.
“This new UK site will not only support our ambitions for future drug discovery but will be well-placed to enable us to achieve our 2030 global sustainability goals and provides an environment which supports the physical and mental wellbeing of our people – essential to helping us thrive,” added Tellier.
By Lucy Parsons
Source: pharmatimes.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.